Eli Lilly and Co., US5324571083

Lam Research stock gains on a $3 billion R&D plan

Published on 08/14/2026 at 16:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lam Research stock is drawing attention after a $3 billion R&D expansion plan and a July 29, 2026 earnings beat that showed $6.72 billion in revenue and $1.82 in EPS.

Wissenschaftler im sterilen Pharma-Labor mit Edelstahl-Bioreaktoren und Laborgeräten
Fotorealistisches Pharma-Labor zeigt Eli Lilly and Company mit ISIN US5324571083 in moderner Forschungsumgebung symbolisch, Illustration mit AI erstellt.

Lam Research stock is in the spotlight after the company said on August 14, 2026, it plans to invest more than $3 billion over five years to expand its global R&D laboratory network, while the shares last closed at $337.01 on August 13, 2026. The same update sits alongside the company's July 29, 2026 earnings beat, where revenue reached $6.72 billion and EPS came in at $1.82.

R&D spending gets bigger

The new laboratory network plan is designed to lift experiment capacity by more than 50%, according to the August 14, 2026 market wrap that carried the company update. That scale matters because Lam Research's last reported quarter already showed $6.72 billion in revenue, a 30.0% increase from the same quarter a year earlier.

For investors, the combination of higher R&D spend and a 30.0% year-over-year revenue gain points to an equipment maker still leaning into process development while demand stays firm. The recent quarter also topped expectations by $0.13 per share, with EPS at $1.82 versus $1.69 consensus.

Latest earnings still matter

Lam Research's most recent quarter was reported on July 29, 2026, and it also showed a strong margin backdrop, with net margin at 31.27% and return on equity at 67.60% in the same market summary. Management added first-quarter fiscal 2027 EPS guidance of $2.00 to $2.30, which sits above the $1.81 consensus figure cited in the same report.

That gap between guidance and consensus is the key comparison right now. Revenue guidance for the next quarter was set at $7.7 billion to $8.5 billion, against a $7.0 billion consensus estimate, which gives the market a concrete benchmark for the next reporting step.

What the product push means

Lam Research's toolset centers on semiconductor manufacturing equipment used in wafer processing, deposition, etch, and clean steps. The R&D buildout is aimed at shortening development cycles from pathfinding through fab deployment, which fits a business that depends on faster node transitions and close customer collaboration.

Shares and valuation

Lam Research stock closed at $337.01 on August 13, 2026, with a market cap of $421.71 billion in the same market snapshot. The same quote page put the next earnings date at October 21, 2026, which gives investors a clear calendar marker after the July 29, 2026 report.

Fact box

Company: Lam Research Corporation
ISIN: US5324571083
Ticker: LRCX
Exchange: Nasdaq
Price (as of August 13, 2026, 4:00 p.m. ET): $337.01 USD
Market cap: $421.71 billion (as of August 14, 2026)
Sector / Industry: Technology / Semiconductor Equipment
Index membership: Nasdaq-100
Next earnings date: October 21, 2026

Disclaimer...

en | US5324571083 | ELI LILLY AND CO. | boerse | 69949703 | bgmi